Rodman & Renshaw initiated coverage of Karyopharm (KPTI) with a Buy rating and $28 price target The firm is positive on selinexor’s “differentiated” mechanism of action and “compelling” Phase 1 combination data in myelofibrosis. The drug’s peak revenue opportunity of $800M-$850M in frontline myelofibrosis alone is “substantial” with additional upside from ongoing the multiple myeloma programs, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI:
- Karyopharm Amends Credit Agreement to Extend Liquidity Runway
- Karyopharm Shareholders Approve Major Authorized Share Increase
- Buy Rating Reaffirmed on De‑Risked SENTRY Readout and Undervalued Selinexor Cash Flow Potential
- Karyopharm Therapeutics Faces Rising Regulatory and Political Risks Amid Supreme Court Limits on FDA Authority
- Karyopharm Earnings Call: Pivotal Data Amid Cash Squeeze